231 related articles for article (PubMed ID: 21029829)
1. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Kajimoto K; Imai T; Minami Y; Kasanuki H
Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
[TBL] [Abstract][Full Text] [Related]
2. Advances in medical treatment of hypertrophic cardiomyopathy.
Hamada M; Ikeda S; Shigematsu Y
J Cardiol; 2014 Jul; 64(1):1-10. PubMed ID: 24735741
[TBL] [Abstract][Full Text] [Related]
3. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
Hamada M; Ikeda S; Ohshima K; Nakamura M; Kubota N; Ogimoto A; Shigematsu Y
J Cardiol; 2016 Mar; 67(3):279-86. PubMed ID: 26116980
[TBL] [Abstract][Full Text] [Related]
4. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
Tokudome T; Mizushige K; Ueda T; Sakamoto S; Matsuo H
Angiology; 1999 Apr; 50(4):331-5. PubMed ID: 10225470
[TBL] [Abstract][Full Text] [Related]
5. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles.
Hamada M; Aono J; Ikeda S; Watanabe K; Inaba S; Suzuki J; Ohtsuka T; Shigematsu Y
Circ J; 2007 Oct; 71(10):1540-4. PubMed ID: 17895548
[TBL] [Abstract][Full Text] [Related]
7. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
[TBL] [Abstract][Full Text] [Related]
8. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.
Hamada M; Shigematsu Y; Ikeda S; Hara Y; Okayama H; Kodama K; Ochi T; Hiwada K
Circulation; 1997 Sep; 96(5):1520-4. PubMed ID: 9315541
[TBL] [Abstract][Full Text] [Related]
9. Mid-systolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy--the lobster claw abnormality.
Sherrid MV; Gunsburg DZ; Pearle G
J Am Soc Echocardiogr; 1997 Sep; 10(7):707-12. PubMed ID: 9339420
[TBL] [Abstract][Full Text] [Related]
10. Effect of cibenzoline on regional left ventricular function in hypertrophic obstructive cardiomyopathy.
Kondo I; Mizushige K; Nozaki S; Hirao K; Iwado Y; Ohmori K; Matsuo H
Clin Cardiol; 2000 Sep; 23(9):689-96. PubMed ID: 11016020
[TBL] [Abstract][Full Text] [Related]
11. Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.
Kondo I; Mizushige K; Nozaki S; Iwado Y; Masugata H; Kohno M; Matsuo H
Cardiovasc Drugs Ther; 2001 Sep; 15(5):459-65. PubMed ID: 11855665
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic interactions between Angiotensin-converting enzyme insertion/deletion polymorphism and response to cibenzoline in patients with hypertrophic obstructive cardiomyopathy.
Ogimoto A; Okayama H; Nagai T; Ohtsuka T; Suzuki J; Inoue K; Nishimura K; Saito M; Shigematsu Y; Hamada M; Miki T; Higaki J
J Cardiovasc Pharmacol; 2010 May; 55(5):506-10. PubMed ID: 20179607
[TBL] [Abstract][Full Text] [Related]
13. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.
Minami Y; Kajimoto K; Kawana M; Hagiwara N; Sherrid MV
Int J Cardiol; 2010 May; 141(2):195-7. PubMed ID: 19097655
[TBL] [Abstract][Full Text] [Related]
15. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Verlinden NJ; Coons JC
Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
[TBL] [Abstract][Full Text] [Related]
16. Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.
Sekine T; Daimon M; Hasegawa R; Teramoto K; Kawata T; Tanaka N; Takei Y; Takazawa K; Yoshida K; Komuro I
Heart Vessels; 2006 Nov; 21(6):350-5. PubMed ID: 17143709
[TBL] [Abstract][Full Text] [Related]
17. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.
Hongo M; Nakatsuka T; Takenaka H; Tanaka M; Watanabe N; Yazaki Y; Sekiguchi M
Cardiology; 1996; 87(1):6-11. PubMed ID: 8631046
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
[TBL] [Abstract][Full Text] [Related]
19. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
Haruki S; Minami Y; Suzuki A; Hagiwara N
Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
[TBL] [Abstract][Full Text] [Related]
20. Effect of propranolol and disopyramide on left ventricular function at rest and during exercise in hypertrophic cardiomyopathy.
Hartmann A; Kühn J; Hopf R; Klepzig H; Standke R; Kober G; Maul FD; Hör G; Kaltenbach M
Cardiology; 1992; 80(2):81-8. PubMed ID: 1611637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]